Digital RESI Innovation Challenge
Oxidien Pharmaceuticals is a clinical stage drug development company developing a treatment for enteric hyperoxaluria, a large unmet need in kidney disease. We have excellent safety and efficacy data using our proprietary, oral biologic with significant advantages over products in development. Enteric hyperoxaluria is a condition that affects 250,000 patients in the US alone. The company spun out from Captozyme, Inc., in 2019, before Captozyme was acquired by Arranta Bio in November of 2019. Oxidien is now presenting a de-risked opportunity for an investment partner to come in early as we get ready for a dose-finding Phase 2 study.